State Ledger
Company profile

Bicara Therapeutics Inc. CIK 2023658

Ticker
BCAX (Nasdaq)
Industry
Pharmaceutical Preparations
Headquarters
Boston, MA 02116
Fiscal year end
2025 (FY)
Market Data
Close
$17.34
Change
-$0.16
Change %
-0.91%
Volume
48,497

BCAX · trading date Oct 12, 2026 · previous close $17.50 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$137.95M
Total assets
$430.99M
Total liabilities
$29.54M
Stockholders' equity
$401.45M
Cash & equivalents
$96.69M
Operating income
-$155.60M
Operating cash flow
-$106.83M
Capital expenditures
$280.0K

Fiscal year 2025, via 10-K filed 2026-03-30. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
-$107.11M
Free cash flow margin
—
Liabilities / assets
6.9%
Equity / assets
93.1%
CapEx / revenue
—
Operating cash flow / net income
0.77×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$137.95M $430.99M $29.54M $401.45M
2024 — -$68.00M $510.00M $18.12M $491.88M
2023 — -$51.99M $233.98M $15.47M -$148.77M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 4
2026-09-10
Financials filed via
Form 10-K
filed 2026-03-30

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Boston, MA 02116
116 HUNTINGTON AVENUE SUITE 703
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:35 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Massachusetts — Public Companies